

Manoj P Menezes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8693996/publications.pdf>

Version: 2024-02-01

56
papers

2,381
citations

279701

23
h-index

214721

47
g-index

71
all docs

71
docs citations

71
times ranked

4487
citing authors

#	ARTICLE	IF	CITATIONS
1	Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. <i>Nature Genetics</i> , 2014, 46, 503-509.	9.4	490
2	Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. <i>Nature Genetics</i> , 2012, 44, 704-708.	9.4	216
3	Mutations in BICD2 Cause Dominant Congenital Spinal Muscular Atrophy and Hereditary Spastic Paraplegia. <i>American Journal of Human Genetics</i> , 2013, 92, 965-973.	2.6	156
4	Treatable childhood neuropathy caused by mutations in riboflavin transporter RFVT2. <i>Brain</i> , 2014, 137, 44-56.	3.7	143
5	Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome. <i>Pediatrics</i> , 2015, 135, e974-e984.	1.0	115
6	An inherited TUBB2B mutation alters a kinesin-binding site and causes polymicrogyria, CFEOM and axon dysinnervation. <i>Human Molecular Genetics</i> , 2012, 21, 5484-5499.	1.4	106
7	Phenotypic and molecular insights into spinal muscular atrophy due to mutations in BICD2. <i>Brain</i> , 2015, 138, 293-310.	3.7	82
8	Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease. <i>JAMA Neurology</i> , 2016, 73, 645.	4.5	71
9	Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 59, 132-140.	0.9	63
10	Eye movement disorders are an early manifestation of <i>CACNA1A</i> mutations in children. <i>Developmental Medicine and Child Neurology</i> , 2016, 58, 639-644.	1.1	58
11	Feasibility of designing, manufacturing and delivering 3D printed ankle-foot orthoses: a systematic review. <i>Journal of Foot and Ankle Research</i> , 2019, 12, 11.	0.7	56
12	Systematic review of exercise for Charcot-Marie-Tooth disease. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 347-362.	1.4	51
13	Natural history of Charcot-Marie-Tooth disease during childhood. <i>Annals of Neurology</i> , 2017, 82, 353-359.	2.8	50
14	Variants in <i>SLC18A3</i> , vesicular acetylcholine transporter, cause congenital myasthenic syndrome. <i>Neurology</i> , 2016, 87, 1442-1448.	1.5	46
15	Nusinersen for SMA: expanded access programme. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 937-942.	0.9	46
16	Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants. <i>Genetics in Medicine</i> , 2022, 24, 130-145.	1.1	45
17	Importance and challenge of making an early diagnosis in <i>LMNA</i> -related muscular dystrophy. <i>Neurology</i> , 2012, 78, 1258-1263.	1.5	41
18	Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial. <i>The Lancet Child and Adolescent Health</i> , 2017, 1, 106-113.	2.7	39

#	ARTICLE	IF	CITATIONS
19	Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. <i>Brain</i> , 2020, 143, 3589-3602.	3.7	39
20	Rapidly progressive asymmetrical weakness in Charcot-Marie-Tooth disease type 4J resembles chronic inflammatory demyelinating polyneuropathy. <i>Neuromuscular Disorders</i> , 2013, 23, 399-403.	0.3	38
21	Preusinersen economic and health-related quality of life burden of spinal muscular atrophy. <i>Neurology</i> , 2020, 95, e1-e10.	1.5	30
22	Peripheral neuropathy associated with mitochondrial disease in children. <i>Developmental Medicine and Child Neurology</i> , 2012, 54, 407-414.	1.1	27
23	Development and validation of the Charcot-Marie-Tooth Disease Infant Scale. <i>Brain</i> , 2018, 141, 3319-3330.	3.7	25
24	Gait patterns of children and adolescents with Charcot-Marie-Tooth disease. <i>Gait and Posture</i> , 2017, 56, 89-94.	0.6	24
25	Genetic, Radiologic, and Clinical Variability in Brown-Vialetto-van Laere Syndrome. <i>Seminars in Pediatric Neurology</i> , 2018, 26, 2-9.	1.0	24
26	Auditory neuropathy in Brown-Vialetto-Van Laere syndrome due to riboflavin transporter RFVT2 deficiency. <i>Developmental Medicine and Child Neurology</i> , 2016, 58, 848-854.	1.1	22
27	Pathophysiology of motor dysfunction in a childhood motor neuron disease caused by mutations in the riboflavin transporter. <i>Clinical Neurophysiology</i> , 2016, 127, 911-918.	0.7	22
28	Balance impairment in pediatric charcot-Marie-Tooth disease. <i>Muscle and Nerve</i> , 2019, 60, 242-249.	1.0	22
29	Magnetic resonance imaging in enterovirus 71, myelin oligodendrocyte glycoprotein antibody, aquaporin 4 antibody, and multiple sclerosis-associated myelitis in children. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 1108-1116.	1.1	22
30	Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3. <i>PLoS Genetics</i> , 2016, 12, e1006177.	1.5	20
31	Inherited neuromuscular disorders: Pathway to diagnosis. <i>Journal of Paediatrics and Child Health</i> , 2012, 48, 458-465.	0.4	19
32	The First Case of Riboflavin Transporter Deficiency in sub-Saharan Africa. <i>Seminars in Pediatric Neurology</i> , 2018, 26, 10-14.	1.0	19
33	Surgical outcomes of cavovarus foot deformity in children with Charcot-Marie-Tooth disease. <i>Neuromuscular Disorders</i> , 2019, 29, 427-436.	0.3	18
34	Whole exome sequencing identifies three recessive FIG4 mutations in an apparently dominant pedigree with Charcot-Marie-Tooth disease. <i>Neuromuscular Disorders</i> , 2014, 24, 666-670.	0.3	17
35	Magnetic resonance imaging pattern recognition in childhood bilateral basal ganglia disorders. <i>Brain Communications</i> , 2020, 2, fcaa178.	1.5	17
36	Delayed diagnosis of congenital myasthenia due to associated mitochondrial enzyme defect. <i>Neuromuscular Disorders</i> , 2015, 25, 257-261.	0.3	16

#	ARTICLE	IF	CITATIONS
37	Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease. <i>Journal of the Peripheral Nervous System</i> , 2013, 18, 177-180.	1.4	15
38	Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease. <i>Mitochondrion</i> , 2016, 30, 162-167.	1.6	13
39	Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 530-538.	0.9	10
40	Randomised controlled trial protocol of foot and ankle exercise for children with Charcot-Marie-Tooth disease. <i>Journal of Physiotherapy</i> , 2014, 60, 55.	0.7	9
41	Magnetic resonance imaging of the anterior compartment of the lower leg is a biomarker for weakness, disability, and impaired gait in childhood Charcot-Marie-Tooth disease. <i>Muscle and Nerve</i> , 2019, 59, 213-217.	1.0	7
42	Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1713-1715.	1.7	5
43	Clinical, Genetic, and Disability Profile of Pediatric Distal Hereditary Motor Neuropathy. <i>Neurology</i> , 2021, 96, e423-e432.	1.5	5
44	Yield of comparative genomic hybridization microarray in pediatric neurology practice. <i>Neurology: Genetics</i> , 2019, 5, e367.	0.9	4
45	Psychiatric comorbidity is common in dystonia and other movement disorders. <i>Archives of Disease in Childhood</i> , 2021, 106, 62-67.	1.0	4
46	Unique clinical and neurophysiologic profile of a cohort of children with CMTX3. <i>Neurology</i> , 2018, 90, e1706-e1710.	1.5	3
47	Established and novel measures of upper limb impairment in children with Charcot-Marie-Tooth disease type 1A and riboflavin transporter deficiency type 2. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 29-35.	1.4	3
48	Prominent scapulae mimicking an inherited myopathy expands the phenotype of CHD7-related disease. <i>European Journal of Human Genetics</i> , 2016, 24, 1216-1219.	1.4	2
49	Association Between Body Mass Index and Disability in Children With Charcot-Marie-Tooth Disease. <i>Neurology</i> , 2021, 97, e1727-e1736.	1.5	2
50	Reply: The p.Ser107Leu inBICD2is a mutation "hot spot" causing distal spinal muscular atrophy. <i>Brain</i> , 2015, 138, e392-e392.	3.7	1
51	Functional outcome measures for infantile Charcot-Marie-Tooth disease: a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 99-107.	1.4	1
52	Response. <i>Neuromuscular Disorders</i> , 2015, 25, 360.	0.3	0
53	Reliability and sensitivity of radiographic measures of hip dysplasia in childhood Charcot-Marie-Tooth disease. <i>HIP International</i> , 2021, , 112070002110275.	0.9	0
54	Replicating and redesigning ankle-foot orthoses with 3D printing for children with Charcot-Marie-Tooth disease. <i>Gait and Posture</i> , 2022, 96, 73-80.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Paediatric neurocysticercosis in high income countries. European Journal of Paediatric Neurology, 2022, 39, 88-95.	0.7	0
56	Advances in the management of <scp>Charcotâ€“Marieâ€“Tooth</scp> disease in childhood. Developmental Medicine and Child Neurology, 2022, 64, 931-932.	1.1	0